Agentic operating system for pharma operations: AI agents for batch investigations, process monitoring and deviation management
Katalyze AI builds agentic infrastructure for pharmaceutical operations. Its platform unifies fragmented pharma systems into a single data layer and lets scientists deploy teams of expert-designed AI agents on top to automate engineering, scientific and manufacturing work such as batch investigations, process monitoring and deviation management. The company says five of the world's 20 largest pharma companies, including Sanofi, run Katalyze, that 10 million doses have been deployed through it, and that customers see 40% faster batch release and deviation investigations cut by 50% (company claims). Co-founder and CEO Reza Farahani (University of Waterloo) previously co-founded and sold HR software startup WFHomie; co-founder and COO Shreyas Becker was head of AI and data products for manufacturing and supply at Sanofi in Toronto; Hannes Bretschneider is Chief AI Officer. Dual-headquartered in Toronto and San Francisco with about 40 staff. In July 2026 it raised a $10.5M (C$14.9M) seed led by Bonfire Ventures with Inovia Capital, Ripple Ventures and Alumni Ventures. Its stated aim is to halve the eight to twelve years and $2B+ it takes to bring a drug to market by 2030.
AI📍 Toronto, Canada / San Francisco, CA
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Katalyze AI going public?
No. Katalyze AI is private and has not filed to go public. There is no S-1 on file.
What is Katalyze AI's valuation in 2026?
No confirmed valuation is on record for Katalyze AI. The roster shows funding and investors where they are public; it does not estimate a mark.
Katalyze AI has raised $10.5M in total across 1 disclosed round, most recently a Seed of $10.5M in Jul 2026.
Is Katalyze AI publicly traded — can you buy Katalyze AI stock?
No. Katalyze AI is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Katalyze AI on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Reza Farahani
HQ
Toronto, Canada / San Francisco, CA
Employees
40
Total Raised
$10.5M
Growth
Deployed at 5 of the top 20 pharma companies; 10M doses through the platform (company claims)
Last Round
Seed — $10.5M (Jul 2026) · Lead: Bonfire Ventures
IPO Status
private
Fundraising Status
Seed · $10.5M · 3 mo ago
privateTotal raised $10.5M1 disclosed rounds
Funding History
Round
Amount
Date
Lead Investor
Post-Money
Seed
$10.5M
Jul 2026
Bonfire Ventures
—
Vertical Intelligence — Biotech / Gene Therapy
Biotech / Gene Therapy registry data for Katalyze AI has not been collected yet — the weekly vertical sweep hasn't reached this company. Check back soon.
Talent Signal
Hiring data for Katalyze AI has not been collected yet — the monthly talent sweep hasn't reached this company. Check back soon.
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.